Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results March 04, 2021 16:42 ET | Source: Cellectis Inc. Cellectis Inc. New York, New York, UNITED STATES Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers Preliminary results from our Phase 1 BALLI-01 clinical study of UCART22 in adults with r/r B-ALL presented in oral session at 2020 ASH Annual Meeting Partner A...
Source: globenewswire.com